Novartis has agreed to acquire Myricx Bio, a UK-based oncology company developing novel antibody-drug conjugates (ADCs), for up to $1.5 billion including $1.1 billion upfront. This acquisition combines Novartis's oncology expertise with Myricx Bio's innovative N-myristoyltransferase inhibitor (NMTi) payload platform, potentially improving cancer treatment for multiple solid tumors. Brandon Capital, a leading life sciences venture firm, played a key role in Myricx Bio's formation and growth, supporting its strategic pivot to ADCs and securing significant returns for its investors. The deal is expected to close in the second half of 2026, pending regulatory approvals.

More News (NVS)

Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

Novartis has agreed to acquire UK biotech Myricx Bio for up to $1.5 billion, including $1.1 billion cash upfront, to enhance its oncology portfolio with Myricx's novel antibody-drug conjugate (ADC) payloads. Myricx Bio specializes in a first-in-class...

Company Fundamentals

Bullish

2 hours ago

Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

More News (NVS)

Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Novartis to acquire Myricx Bio for up to $1.5B, advancing new cancer therapies with innovative ADC technology.

More News (NVS)

Novartis to acquire Myricx Bio for up to $1.5B to advance novel cancer ADC therapies.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App